Cargando…
Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?
Autor principal: | Tefferi, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3768111/ https://www.ncbi.nlm.nih.gov/pubmed/23604230 http://dx.doi.org/10.1038/leu.2013.112 |
Ejemplares similares
-
When calculation of minimum sample size is not justified: When sample size calculation is not justified
por: Pourhoseingholi, Mohamad Amin, et al.
Publicado: (2011) -
Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro
por: Blake, Stephen J, et al.
Publicado: (2009) -
First case report of latent tuberculosis reactivation complicating treatment with nilotinib in chronic myeloid leukemia
por: Kim, Da Jung, et al.
Publicado: (2019) -
Is a minimum dose of atropine in children justified?
por: Prakash, Smita, et al.
Publicado: (2017) -
Can Limited Scientific Value of Potential Pandemic Pathogen Experiments Justify the Risks?
por: Lipsitch, Marc
Publicado: (2014)